1. Home
  2. FBNC vs HAE Comparison

FBNC vs HAE Comparison

Compare FBNC & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp

FBNC

First Bancorp

HOLD

Current Price

$58.37

Market Cap

2.6B

Sector

Finance

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$65.08

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBNC
HAE
Founded
1934
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.9B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
FBNC
HAE
Price
$58.37
$65.08
Analyst Decision
Buy
Buy
Analyst Count
4
9
Target Price
$61.25
$86.00
AVG Volume (30 Days)
179.7K
876.4K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
1.65%
N/A
EPS Growth
45.65
44.54
EPS
2.68
2.46
Revenue
$67,623,000.00
$910,373,000.00
Revenue This Year
$37.82
N/A
Revenue Next Year
$2.30
$5.46
P/E Ratio
$21.55
$26.57
Revenue Growth
N/A
N/A
52 Week Low
$34.50
$47.32
52 Week High
$62.64
$87.32

Technical Indicators

Market Signals
Indicator
FBNC
HAE
Relative Strength Index (RSI) 48.68 53.47
Support Level $45.57 $65.03
Resistance Level $62.53 $67.63
Average True Range (ATR) 2.04 1.93
MACD -0.53 1.19
Stochastic Oscillator 42.91 91.03

Price Performance

Historical Comparison
FBNC
HAE

About FBNC First Bancorp

First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: